Respiratory Medicine
Volume 104, Issue 12 , Pages 1919-1928 , December 2010

Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients

  • R. Jackson

      Affiliations

    • Research Service (151), Miami VAHS, 1201 NW 16th Street, Miami, FL 33125, USA
    • University of Miami, Miami, FL 33101, USA
    • Corresponding Author InformationCorresponding author at: Research Service (151), Miami VAHS, 1201 NW 16th Street, Miami, FL 33125. Tel.: +1 305 575 3548/305 632 2687; fax: +1 305 575 3126.
    • ,
  • C. Ramos

      Affiliations

    • Research Service (151), Miami VAHS, 1201 NW 16th Street, Miami, FL 33125, USA
    • ,
  • C. Gupta

      Affiliations

    • Research Service (151), Miami VAHS, 1201 NW 16th Street, Miami, FL 33125, USA
    • ,
  • O. Gomez-Marin

      Affiliations

    • Research Service (151), Miami VAHS, 1201 NW 16th Street, Miami, FL 33125, USA
    • University of Miami, Miami, FL 33101, USA

Received 19 February 2010 ,Accepted 27 July 2010.

References 

  1. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277–304
  2. Wells A, Hirani N. Interstitial lung disease guideline: the british thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society. Thorax. 2008;63:v1–v58
  3. Kinnula V. Redox imbalance and lung fibrosis. Antioxid Redox Signal. 2008;10:249–252
  4. Rahman I, Skwarska E, Henry M, Davis M, O’Connor C, FitzGerald M, et al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med. 1999;27:60–68
  5. Yildrim Z, Kotuk M, Iraz M, Kuku I, Ulu R, et al. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine. Pulm Pharmacol Ther. 2005;18:367–373
  6. Serrano-Mollar A, Closa D, Prats N, Blesa S, et al. In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol. 2003;138:1037–1048
  7. Bowler R, Nicks M, Warnick K, Crapo J. Role of extracelluar superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2002;282:L719–L726
  8. Day B. Antioxidants as potential therapeutics for lung fibrosis. Antioxid Redox Signal. 2008;10:355–370
  9. Hye-Young C, Reddy S, Yamamoto M, Kleeberger S. The transcription factor Nrf2 protects against pulmonary fibrosis. FASEB J. 2004;18:1258–1260
  10. Demedts M, Behr J, Buhl R, Constable U, Dekhuijzen R, Jansen H, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–2242
  11. Felton V, Borok Z, Willis B. N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Molec Physiol. 2009;297:L805–L812
  12. Cantin A, North S, Fells G, Hubbard R, Crystal R. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987;79:1665–1673
  13. Cantin A, Hubbard R, Crystal R. Glutathione deficiency in the epithelial lining fluid of lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1988;139:370–372
  14. Behr J, Maier K, Degenkob B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med. 1997;156:1897–1901
  15. Fu X, Kassim S, Parks W, Heinecke J. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin). An oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem. 2003;278:28403–28409
  16. Kinnula V, Fattman C, Tan R, Oury T. Oxidative stress in pulmonary fibrosis. A possible role for redox modulatory therapy. Am J Respir Crit Care Med. 2005;172:417–422
  17. Jackson R, Ramos C, Glassberg M, Bejarano P, Gomez-Marin O. Vasodilator therapy and exercise tolerance in idiopathic pulmonary fibrosis: A randomized, placebo controlled trial of sildenafil. Lung. 2010;188:115–123
  18. Leuchte H, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Resp Crit Care Med. 2004;170:360–365
  19. Elin R, Winter W. Laboratory and clinical aspects of b-type natriuretic peptides. Arch Pathol Lab Med. 2004;128:697–699
  20. Lundholm L, Mohme-Lundholm E, Vamos N. Lactic acid assay with L(+) lactic acid dehydrogenase from rabbit muscle. Acta Physiol Scand. 1963;58:243–249
  21. Haschke M, Zhang YL, Kahle C, Klawitter J, Korecka M, Shaw L, et al. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin Chem. 2007;53:489–497
  22. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J Chromatogr. 2007;851:51–70
  23. de Andrade J, Crow J, Viera L, Alexander C, Young K, McGiffin D, et al. Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts. Am J Respir Crit Care Med. 2000;161:2035–2042
  24. Frei B, Stocker R, Ames B. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci. 1988;85:9748–9752
  25. Long L, Evan P, Halliwell B. Hydrogen peroxide in human urine: implications for antioxidant defense and redox regulation. Biochem Biophys Res Commun. 1999;262:605–609
  26. Basu S. F2-Isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal. 2008;10:1405–1434
  27. Becker A, Uckert S, Tsikas D, Noack H, Stief C, Frolich J, et al. Determination of nitric oxide metabolites by means of the Griess assay and gas chromatography-mass spectrometry in the cavernous and systemic blood of healthy males and patients with erectile dysfunction during different functional conditions of the penis. Urol Res. 2000;28:364–369
  28. Markart P, Luboeinski T, Korfei M, Schmidt R, Wygrecka M, Mahavida P, et al. Alveolar oxidative stress is associated with elevated levels of nonenzymatic low-molecular weight antioxidants in patients with different forms of chronic fibrosing interstitial lung disease. Antioxid Redox Signal. 2009;11:227–240
  29. Saleh D, Barnes P, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:1763–1769
  30. Koechlin C, Maltais F, Saey D, Michaud A, LeBlanc P, Hayot M, et al. Hypoxemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease. Thorax. 2005;60:834–841
  31. Richardson R, Duteil S, Wary D, Wray D, Hoff J, Carlier P. Human skeletal muscle intracellular oxygenation: the impact of ambient oxygen availability. J Physiol. 2006;571:415–424
  32. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J. 1994;7:431–436
  33. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med. 1995;152:1055–1060
  34. Katsoulis K, Kontakiotis T, Leonardopoulos I, Kotsovili A, Legakis I, Patakas D. Serum total antioxidant status in severe exacerbation of asthma: correlation with the severity of the disease. J Asthma. 2003;40:847–854
  35. Nadeem A, Raj H, Chhabra S. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation. 2005;29:23–32
  36. Cowley H, Bacon P, Pamela J, Goode H, Webster N, Jones G, et al. Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. Crit Care Med. 1996;24:1179–1183
  37. Banerfjee D, Madhusoodanan U, Nayak S, Jacob J. Urinary hydrogen peroxide: a probable marker of oxidative stress in malignancy. Clin Chim Acta. 2009;334:205–209
  38. Baldus S, Eiserich J, Jackson R, Alexander C, Freeman B. Spatial mapping of nitrotyrosine in vascular and pulmonary inflammatory diseases reveals a pivotal role for myeloperoxidase as a catalyst for tyrosine nitration in vivo. Free Radic Biol Med. 2002;33:1010–1019
  39. Cerretelli P, Samaja M. Acid-base balance at exercise in normoxia and in chronic hypoxia. Revisiting the "lactate paradox.". Eur J Appl Physiol. 2003;90:431–448
  40. Rush J, Turk J, Laughlin M. Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium. Am J Physiol Circ Physiol. 2003;284:H1378–H1387
  41. Sen C. Oxidants and antioxidants in exercise. J Appl Phys. 1995;79:675–686
  42. McArdle A, van der Meulen J, Close G, Pattwell D, Van Remmen H, Huang T, et al. Role of mitochondrial superoxide dismutase in contraction-induced generation of reactive oxygen species in skeletal muscle extracellular space. Am J Physiol, Cell Physiol. 2004;286:C1152–C1158
  43. Viña J, Servera E, Asensi M, Sastre J, Pallardó F, Ferrero J, et al. Exercise causes blood glutathione oxidation in chronic obstructive pulmonary disease: prevention by O2 therapy. J Appl Phys. 1996;81:2199–2202
  44. Heunks L, Viña J, Van Herwaaden C, Folgering T, Gimeno A, Dekhuijzen R. Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Phys. 1999;277:R1697–R1704(Regulatory Integrative Comp Physiol 46)
  45. McArdle F, Spiers S, Aldemir H, Vasilaki A, Beaver A, Iwanejko L, et al. Preconditioning of skeletal muscle against contraction-induced damage: the role of adaptations to oxidants in mice. J Physiol. 2004;561:233–244
  46. Mercken E, Hageman G, Schols A, Akkermans M, Bast A, Wouters E. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:994–1001

PII: S0954-6111(10)00342-2

doi: 10.1016/j.rmed.2010.07.021

Respiratory Medicine
Volume 104, Issue 12 , Pages 1919-1928 , December 2010

Article Tools

* Image Usage & Resolution